The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT), two clinical-stage drugmakers, have seen their shares skyrocket. The reason? Both companies announced promising clinical progress ...
motleyfoolusx:vktxusx:smmt
Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue to grow incredibly fast. Nvidia's shares are up by 137% this year. Some companies have performed even ...
motleyfoolusx:smmt
If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for owning a piece of the business. And in some cases, those valuations can appear extreme, especially when you consider the risk that investors are taking on. One biotech company which ...
motleyfoolusx:smmt
Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed 123.4% higher this week through Thursday trading, according to data from S&P Global Market Intelligence. A biotech stock surging that much usually means a new blockbuster drug candidate either posted good trial data or was approved for use. That's ...
motleyfoolusx:smmt
Shares of Summit Therapeutics (NASDAQ: SMMT) were soaring 22.5% higher as of 11:18 a.m. ET on Thursday. The gain came after the clinical-stage biopharmaceutical company revealed that it entered into agreements with several biotech institutional and individual accredited investors for the sale of over ...
motleyfoolusx:smmt
Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. The biotech firm released the results of a Phase III study on Sunday at the 2024 World Conference on Lung Cancer in San Diego. The data showed its lung cancer treatment ...
motleyfoolusx:mrkusx:smmt
